TX HB4014

Directs the Health and Human Services Commission to conduct a study on psychedelic therapies—specifically MDMA, psilocybin, and ketamine—for treating PTSD, depression, and other co-occurring conditions

Requires consultation with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at UT Austin

Study must review clinical trials, current literature, and FDA actions on psychedelic therapies, as well as evaluate treatment guidelines and patient access issues including provider availability, affordability, training, and licensure

Written report with findings and legislative recommendations due to the governor, lieutenant governor, speaker, and relevant committee chairs by December 1, 2026

Commission may accept federal funds, gifts, grants, or donations to finance the study; implementation contingent on legislative appropriations; Act expires September 1, 2027